

AMD070



Drug Class: Entry and Fusion Inhibitors

AMD070, also known as AMD11070, is a type of medicine called a CXCR4 inhibitor. This type of medicine works by blocking the entry of HIV into cells.

HIV/AIDS-Related Uses

AMD070 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. It is being studied for the treatment of HIV infection. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

Dosage Form/Administration

AMD070 comes in capsule form and is being studied to determine whether it should be taken with or without food. A solution form has been studied in animals in preclinical trials.

Contraindications

Individuals should tell a doctor about any medical problems before taking this medicine.

Possible Side Effects

Along with its desired effects, AMD070 can cause some unwanted effects. Because this drug has not been studied extensively in people, these effects are not yet known. In animal studies, the most common side effects are vomiting and diarrhea, which usually occur within 1 to 2 hours of taking the drug. Other side effects include changes in the bone marrow and thymus, elevated heart rate, and changes in blood pressure.

Drug and Food Interactions

A doctor should be notified of any other medications being taken, including prescription, nonprescription (over-the-counter), or herbal medications.

Clinical Trials

For information on clinical trials that involve AMD070, visit the ClinicalTrials.gov web site at <http://www.clinicaltrials.gov>. In the Search box, enter: AMD070 AND HIV Infections.

Manufacturer Information

AMD070
AnorMED Inc.
#200-20353 64th Avenue
Langley, BC Canada
604-530-1057

For More Information

Contact your doctor or an AIDSinfo Health Information Specialist:

- Via Phone: 1-800-448-0440 Monday - Friday, 12:00 p.m. (Noon) - 5:00 p.m. ET
- Via Live Help: http://aidsinfo.nih.gov/live_help Monday - Friday, 12:00 p.m. (Noon) - 4:00 p.m. ET